Steve R. Bailey
@Frazier Life Sciences Management, L.p.
Latest period2024 - Q3ReportedManaged Assets$2.495BTotal holdings53
Assets growth rate16.72%Assets growth rate (2-Q avg)3.46%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Frazier Life Sciences Management, L.p.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 53 positions.
Assets under management
The assets under management (AUM) of Frazier Life Sciences Management, L.p. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2.495B in assets, with a quarterly growth rate of 16.72% and a 2-quarter average growth rate of 3.46%. The portfolio is managed by Steve R. Bailey, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
PCVXVaxcyte Inc
| 4.03% | $100.49M 879,405 shares@ $114.27 avg price | Decreased -15.39% |
EWTXEdgewise Therapeutics Inc
| 3.04% | $75.609M 2.833M shares@ $26.69 avg price | Decreased -24.07% |
RCKTRocket Pharmaceuticals Inc
| 1.1% | $27.44M 1.486M shares@ $18.47 avg price | Decreased -4.84% |
TYRATyra Biosciences Inc
| 0.69% | $17.186M 731,020 shares@ $23.51 avg price | Decreased -12.16% |
PEPGPepgen Inc
| 0.25% | $6.008M 702,694 shares@ $8.56 avg price | Decreased -53.24% |